AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31665912
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intrapancreatic autologous stem cell (ASC) infusion and hyperbaric oxygen treatment (HBOT)
Trial: 20717048
Drug: Anterior lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior lens capsule
Trial: 19615288
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg orally daily + vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Trial: 19615288
Drug: Vinorelbine 25-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25-30 mg/m² i.v. on D1 and D8 + cisplatin 70-80 mg/m² i.v. on D1
Trial: 17414229
Drug: Prasugrel (LD/MD:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (LD/MD: 20/5 mg, 30/7.5 mg, 40/10 mg, 60/15 mg)
Trial: 17414229
Drug: Prasugrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel plus ASA (325 mg)
Trial: 11853116
Drug: Drug-free and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free and drug-naive patients
Trial: 2804589
Drug: Adjusted low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted low dose heparin prophylaxis
Trial: 2804589
Drug: Fixed low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed low dose heparin prophylaxis (calcium heparin 5000 units, 8‐hourly)
Trial: 5328359
Drug: Protryptiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protryptiline (10 mg three times daily, max 60 mg daily)
Trial: 29354915
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acupoint catgut-embedding therapy and auricular point pressure
Trial: 23322522
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of epirubicin and paclitaxel alone or with capecitabine (TEX)
Trial: 17185877
Drug: Mitiglinide regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitiglinide regimen (mitiglinide combined with once daily insulin glargine)
Trial: 17185877
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin regimen (multiple daily insulin regimen of aspart insulin and glargine)
Trial: 14678008
Drug: 4.5% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5% human albumin solution (HAS)
Trial: 2519937
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg of 0.5% bupivacaine IP
Trial: 1101457
Drug: Cyclandelate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (200 mg four times daily for six weeks)
Trial: 30987704
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (oral) for 2 months
Trial: 16817274
Drug: Point application
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point application at Yishu, Pishu, Sanyinjiao, Zusanli, and interference therapy of controlling diet
Trial: 16817274
Drug: Interference therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interference therapy of controlling diet
Trial: 10360858
Drug: Ropivacaine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1.2 mg/kg
Trial: 10360858
Drug: Ropivacaine 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 1.8 mg/kg
Trial: 23338109
Drug: Lidocaine 3
RxNorm normalized name: Lidocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 3 mg/kg
Trial: 7075649
Drug: Pindolol 15
RxNorm normalized name: pindolol 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 15 mg twice daily
Trial: 7075649
Drug: Pindolol 30
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol 30 mg retard once daily
Trial: 7075649
Drug: Pindolol 30
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol 30 mg retard
Trial: 28427403
Drug: 12.5% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5% maltodextrin (200 ml, 2 h before anesthesia) without ω-3 PUFA (CHO, n=14)
Trial: 28427403
Drug: 12.5% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5% maltodextrin (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (CHO + W3, n=15)
Trial: 28427403
Drug: Water (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (200 ml, 2 h before anesthesia) plus intraoperative ω-3 PUFA (0.2 mcg/kg) (W3, n=14)
Trial: 28427403
Drug: Water (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (200 ml, 2 h before anesthesia) without ω-3 PUFA (controls, n=14)
Trial: 18063411
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) treatment
Trial: 25773465
Drug: 0.5% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% menthol gel
Trial: 30861160
Drug: 4-mg FDA-approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-mg FDA-approved nasal spray
Trial: 30861160
Drug: 2-mg FDA-approved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mg FDA-approved autoinjector
Trial: 30861160
Drug: Improvised nasal
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Improvised nasal naloxone device (INND) administered twice (2 mg each, separated by 2 minutes)
Trial: 29928996
Drug: ACT+CEE (Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT+CEE (Combination of ACT and CEE)
Trial: 18722112
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) followed by breast conservation surgery with axillary dissection and radiation
Trial: 17204566
Drug: Chondroitin sulphate
RxNorm normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulphate (1 g/day)
Trial: 9474617
Drug: Winstrol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Winstrol (6 mg per day) for 16 ± 9 weeks
Trial: 2191444
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with antibiotic therapy
Trial: 2191444
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with adrenal corticosteroid therapy
Trial: 205020
Drug: Prophylactic adenine
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic adenine arabinoside (Ara-A) at a dose of 5 mg/kg/day administered intravenously on an intermittent schedule
Trial: 30634878
Drug: Conventional mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional mirror book (MB) therapy
Trial: 19785937
Drug: BMMC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMMC therapy
Trial: 8147083
Drug: Re-activating occupational
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-activating occupational therapy (study group)
Trial: 29206647
Drug: Acute intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intravenous sodium loading (hypertonic saline 5 mmol sodium/liter body water for 30 minutes)
Trial: 29206647
Drug: Acute intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute intravenous sodium loading
Trial: 20480060
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 1 g of F-containing dentifrice (0.32% NaF)
Trial: 2246313
Drug: Standard antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antibiotic bowel preparation
Trial: 2246313
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antibiotic bowel preparation)
Trial: 27863480
Drug: Patient-centered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centered cognitive behavioral therapy intervention group
Trial: 22162534
Drug: GSK1521498 (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 (2, 5, and 10 mg) administered once daily for 10 days
Trial: 22162534
Drug: GSK1521498 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1521498 (10 mg) administered once daily for 10 days
Trial: 18386046
Drug: EBM course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBM course in combination with case method learning sessions (CMLSs)
Trial: 7723464
Drug: Data base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data base approach to assess relative efficacy of alternative therapies
Trial: 7723464
Drug: Recording reasons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recording reasons for therapy selection
Trial: 2107581
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro‐ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR)
Trial: 7410745
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (Theophylline, Terbutaline, Prednisone)
Trial: 30269276
Drug: 60 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 leucovorin (LV)
Trial: 30269276
Drug: 200 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m2 leucovorin (LV)
Trial: 30269276
Drug: 500 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2 leucovorin (LV)
Trial: 30269276
Drug: 0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/m2 leucovorin (LV) (untreated)
Trial: 26818098
Drug: EQ‐5D‐3 L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ‐5D‐3 L
Trial: 23432730
Drug: Brinzolamide-timolol fixed
RxNorm normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brinzolamide-timolol fixed combination
Trial: 21115134
Drug: GoLytely (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoLytely (4 L split-dose)
Trial: 21115134
Drug: MiraLAX with
RxNorm normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiraLAX with lubiprostone (24 μg)
Trial: 21115134
Drug: MiraLAX with
RxNorm normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiraLAX with bisacodyl (10 mg)
Trial: 18932058
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with 500 mg alpha‐tocopherol and 2 g vitamin C for 12 weeks
Trial: 11342473
Drug: 2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg IVIG
Trial: 1411634
Drug: Combination cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination cisplatin and carboplatin plus doxorubicin/hexamethylmelamine/cyclophosphamide
Trial: 1411634
Drug: Intravenous carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous carboplatin (350 mg/m2 on day 1) plus oral cyclophosphamide (100 mg/m2 days 2 to 6)
Trial: 1411634
Drug: High-dose carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carboplatin (800 mg/m2)
Trial: 26951379
Drug: Fotemustine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fotemustine (75 mg/m² on days 1, 8, and 15, then 100 mg/m² every 3 weeks after a 35-day interval)
Trial: 24702886
Drug: deep inhalation
RxNorm normalized name: Deep Sea Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deep inhalation methacholine challenge
Trial: 20703472
Drug: Intrasphincteric injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasphincteric injection of botulinum toxin (BT)
Trial: 19017911
Drug: G. biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. biloba (120 mg twice daily)
Trial: 16018146
Drug: Intranasal 17
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 17 beta‐estradiol 300 microg daily
Trial: 8923016
Drug: Chemopreventive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemopreventive agents
Trial: 1553935
Drug: Alprazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.25 mg, three times a day)
Trial: 3159407
Drug: diazepam 0.2
RxNorm normalized name: diazepam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 0.2 mg kg‐1 i.v.
Trial: 3159407
Drug: midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.05 mg kg‐1 i.v.
Trial: 3159407
Drug: midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.1 mg kg‐1 i.v.
Trial: 23448285
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment (pelvic floor muscle training, delayed voiding, urge suppression techniques)
Trial: 23448285
Drug: Antimuscarinic drug
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic drug therapy (extended-release oxybutynin)
Trial: 23448285
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment (for those with ≥2 episodes nocturia at baseline)
Trial: 23448285
Drug: Antimuscarinic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic therapy (for those with ≥2 episodes nocturia at baseline)
Trial: 18799365
Drug: C&G
RxNorm normalized name: Cefuroxime and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C&G
Trial: 11677204
Drug: Antibiotics (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week)
Trial: 11677204
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mg omeprazole twice a day and identical placebos for 1 week)
Trial: 11677204
Drug: H. pylori-negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori-negative group (open label 20 mg omeprazole twice a day for 1 week)
Trial: 29912844
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of IXIARO administered 12 months after primary immunization
Trial: 29912844
Drug: No booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No booster dose
Trial: 29912844
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of IXIARO
Trial: 24627290
Drug: Gemigliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin (50 mg once daily) and Metformin (1,000 mg twice a day)
Trial: 24627290
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg twice a day)
Trial: 22278162
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (hot pack, ultrasound therapy, friction massage)
Trial: 11602481
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave treatment (ESWT)
Trial: 12456445
Drug: Tramadol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol infusion (1 mg/kg loading dose, 0.2 mg/kg/h postoperative infusion)
Trial: 12456445
Drug: Morphine PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCA alone (control group)
Trial: 2031819
Drug: i.v. atropine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. atropine 0.5 mg
Trial: 2031819
Drug: i.v. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. saline 1 ml
Trial: 2031819
Drug: i.v. lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. lignocaine 3 ml with adrenaline 15 micrograms
Trial: 2031819
Drug: adrenaline test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adrenaline test dose
Trial: 7404171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of transbronchial biopsy, alveolar lavage, and radiography
Trial: 31980506
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate lozenges (13 mg elemental zinc, taken six times per day for a maximum of 5 days)
Trial: 31980506
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges (sucrose octa-acetate, taken six times per day for a maximum of 5 days)
Trial: 28628688
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment and nutraceutical (Group 2)
Trial: 28628688
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment (Group 1)
Trial: 15690714
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication therapy; specific dosage and duration not mentioned.
Trial: 8083147
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 5 mg, 10 mg, 15 mg
Trial: 956343
Drug: Meclastine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclastine (oral administration for three days)
Trial: 956343
Drug: Dexchlorpheniramine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexchlorpheniramine (intravenous infusion)
Trial: 7788012
Drug: Insulin hypoglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin hypoglycemia
Trial: 28522450
Drug: Other glucose-lowering
RxNorm normalized name: Other blood glucose lowering drugs, excl. insulins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other glucose-lowering drugs
Trial: 21142844
Drug: Nucleoside and
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV) during first trimester
Trial: 21142844
Drug: Nucleoside and
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV) after first trimester
Trial: 21142844
Drug: Nucleoside and
RxNorm normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside and protease inhibitor antiretroviral therapy (ARV)
Trial: 17336514
Drug: Imatinib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 800 mg daily
Trial: 15062131
Drug: 125I episcleral
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I episcleral plaque radiotherapy (EPRT) with median dose of 80.0 Gy
Trial: 15062131
Drug: 125I episcleral
RxNorm normalized name: fibrinogen (125I)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125I episcleral plaque radiotherapy (EPRT) with median dose of 60.8 Gy
Trial: 6371152
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (20 micrograms per dose)
Trial: 25912588
Drug: valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan (80 mg/d) and atorvastatin (20 mg/d)
Trial: 25912588
Drug: benazepril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril (10 mg/d) and atorvastatin (20 mg/d)
Trial: 23015654
Drug: IGF‐I serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I serum levels in men (137 ± 69 ng/ml for AD)
Trial: 23015654
Drug: IGFBP‐3 serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGFBP‐3 serum levels in men (3675 ± 1542 ng/ml for AD)
Trial: 23015654
Drug: IGFBP‐3 serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGFBP‐3 serum levels in women (3781 ± 1351 ng/ml for AD)
Trial: 19562320
Drug: Reniale (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reniale (autologous tumour cell lysate vaccination therapy)
Trial: 6144974
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adjuvant treatment)
Trial: 11523669
Drug: Hypervolemic hypertensive
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypervolemic hypertensive hemodilution fluid therapy
Trial: 11523669
Drug: Normovolemic fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normovolemic fluid therapy
Trial: 3284630
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg/day) for six weeks